Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143957 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
A Phase 2 study of Phlebotomy Dependent Polycythemia Vera, sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 13
- Study locations
NCT05143957 is a Phase 2 study of Phlebotomy Dependent Polycythemia Vera that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 50 participants. The trial reports 13 study locations across 9 states.
The verdict
NCT05143957, a Phase 2 study of Phlebotomy Dependent Polycythemia Vera, is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 13
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
Conditions Studied
Interventions
- DRUG sapablursen
Study Locations (13)
Other
- Border Medical Oncology Research Unit - Albury
- Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku - Lublin
- Wojewódzki Szpital Specjalistyczny Sp. z o.o. - Słupsk
- MICS Centrum Medyczne Toruń - Torun
- University College London Hospitals NHS Foundation Trust - London
Alabama
- O'Neal Comprehensive Cancer Center University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Hospital - Phoenix
New Jersey
- John Theurer Cancer Center - Hackensack
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- University of Texas MD Anderson Cancer Center - Houston
New South Wales
- Calvary Mater Newcastle Hospital - Waratah
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-12-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05143957
The ClinicalTrials.gov registry entry for NCT05143957 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phlebotomy Dependent Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which sapablursen is the first listed.
NCT05143957 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Other, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05143957 about?
NCT05143957 is a clinical study titled "A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera". The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
What is the current status of trial NCT05143957?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-12-30. Estimated completion is 2026-06.
What conditions does trial NCT05143957 study?
This clinical trial studies the following conditions: Phlebotomy Dependent Polycythemia Vera.
What interventions are being tested in trial NCT05143957?
The interventions under investigation include: sapablursen (DRUG).
Who is sponsoring clinical trial NCT05143957?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143957 being conducted?
This trial has 13 study locations across Alabama, Arizona, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.